Access count of this item: 149

Files in This Item:
File Description SizeFormat 
15_0539.pdf324.52 kBAdobe PDFView/Open
Title: 非麻薬性新鎮痛剤Pentazocineの泌尿器科領域における臨床応用
Other Titles: Clinical studies of pentazocine in urology
Authors: 竹内, 弘幸  KAKEN_name
Author's alias: Takeuchi, Hiroyuki
Keywords: Adolescent
Adult
Aged
Child
Female
Humans
Injections, Intramuscular
Male
Middle Aged
Pain/etiology
Pentazocine/administration & dosage/therapeutic use
Time Factors
Urologic Diseases/drug therapy
Issue Date: Jul-1969
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 15
Issue: 7
Start page: 539
End page: 543
Abstract: For relief of pain, 30 to 60 mg pentazocine in a single dosage was administered intramuscularly to 117 patients hospitalized in the urology ward who complained of severe pains due to urinary calculus, malignant neoplasm, instrumentation or surgical procedure. The following results were obtained. 1) Analgesic effect of pentazocine was observed in 93% of the total patients. 2) Thirty milligram of pentazocine was judged to be equivalent in analgesic potency to 35mg of meperidine and 60mg pentazocine to 10mg morphine. 3) In one patient suffering from chronic pain caused by cancer of the bladder, 360mg pentazocine in maximum was administered for 67 days, 10350mg in total, but neither sign of addiction liability nor psychomimetic effects were observed. 4) Analgesic effect of pentazocine began within 20 minutes in a high percentage of cases and persisted up to four hours after its intramuscular injection. 5) Sedation and sleeping were observed in most of cases after administration of pentazocine. Therefore, it should be given with caution to the out-patients. 6) Other side effects were infrequent. Nausea or vomiting occured in 9%, and other undesirable effects such as euphoria, sweating, dizziness, etc. occured in 5%.
URI: http://hdl.handle.net/2433/120016
PubMed ID: 5388486
Appears in Collections:Vol.15 No.7

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.